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COST-EFFECTIVENESS OF TAMOXIFEN IN 
BREAST CANCER RISK REDUCTION
Sengupta N, Hay JW
Pharmaceutical Economics & Policy, University of Southern 
California, Los Angeles, CA, USA
OBJECTIVE: To determine the cost and cost-effective-
ness of tamoxifen for breast cancer risk reduction. Breast
cancer affects one of every nine American women.
Tamoxifen is the only drug approved by the US FDA for
breast cancer risk reduction. Little research has been
done on cost-effectiveness of this therapy. METHODS: A
cost-effectiveness analysis was used to evaluate the eco-
nomic impact of five-year preventive therapy with
tamoxifen. Data from a large randomized clinical trial
(National Surgical Adjuvant Breast and Bowel Project
P1) were used to develop this cost-effectiveness analysis.
Study participants were a hypothetical cohort of at-risk
US females between age 40 and 75 years. The analysis
was done from a societal perspective, using a 3% annual
discount rate. Health effects were measured by life year
saved and quality adjusted life year (QALY) gained from
the treatment. Cost-effectiveness results were determined
as incremental costs per QALY. RESULTS: Under the
base case assumptions, tamoxifen therapy increased ex-
pected average medical cost $16,838 over five years. The
net five-year average medical cost associated with ther-
apy was $27,365. Average discounted survival benefits
were 0.523 year of life and 0.384 QALY per participant.
This resulted in average cost-effectiveness ratios of
$32,195 per year of life and $43,848 per QALY saved.
Results of the model were relatively insensitive to reason-
able parameter changes. Tamoxifen therapy was substan-
tially more cost-effective for high-risk females ($22,459
per life year and $33,150 per quality adjusted life year).
CONCLUSIONS: The cost per QALY of tamoxifen in
patients at moderate and substantially elevated breast
cancer risk compares favorably with that for many other
standard medical interventions. Therefore, five-year tamox-
ifen therapy is a cost-effective approach for breast cancer
risk reduction.
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VALIDITY OF THE TIME-TRADE OFF 
TECHNIQUE IN DETERMINING PREFERENCES 
FOR THE TREATMENT OF PROSTATE CANCER
Watkins Bruner D, Baron J
Fox Chase Cancer Center, Cheltenham, PA, USA
Several cost-utility studies have shown little or no benefit
for the cost of screening or treatment of asymptomatic
prostate cancer. An important factor in these decision
analyses was subject preference/utility. Preference can be
defined as a subject’s contemplative first choice among a
series of alternatives. Utility is derived from the individ-
ual preferences for a condition or health state. Prefer-
ences are summed and the ensuing value is used to weight
survival or other health outcome. OBJECTIVE: This
study aimed to: 1) assess preferences for radiotherapy,
surgery, hormones, and observation for the treatment of
prostate cancer. METHODS: Fifty men, 25 with and 25
without prostate cancer, were interviewed, using the
Time Trade-Off (TTO) Technique. RESULTS: The men
in this study, regardless of group (cancer vs. no cancer),
showed an increased preference for surgery versus radio-
therapy or hormones, as compared to observation. This
presented logical inconsistencies, since surgery was pre-
sented with twice the risk of impotence and three times
the risk of incontinence as radiotherapy. The validity of
the TTO was therefore assessed by comparing predicted
to actual individual utility scores. For example, the utility
(U) a man placed on an 80% chance of impotence (IP80)
should be half the utility placed on a 40% chance of im-
potence (IP40), if men attended to probabilities of risk.
The observed mean IP80 utility was 0.7957 versus
0.6098 for the predicted (P  0.0002). Similar differ-
ences were found between predicted and observed utility
values for other probabilities of impotence and inconti-
nence. CONCLUSION: Threats to the validity of the
TTO have been documented. Imperfect as the TTO is, it
does provide a more objective process to the traditionally
subjective means by which decisions regarding health
care policy have been made. Therefore, the TTO requires
further testing and modifications to improve validity,
some of which are discussed in this presentation.
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CONVENIENCE IS THE MAIN REASON WHY 
OVARIAN CANCER PATIENTS PREFER 
ORAL REGIMEN
Calhoun EA, Roland PY
Northwestern University, Chicago, IL USA
OBJECTIVE: To examine patients’ preferences and be-
liefs about oral versus intravenous chemotherapy in re-
current ovarian cancer. Despite encouraging short-term
results, most patients ultimately develop recurrence. Sec-
ond-line treatment plays an important role in the care of
this patient population. Quality of life and patient prefer-
ences have not been well studied in this setting. METH-
ODS: Patients who have received 1st line IV therapy an-
swered an investigator-developed survey of ‘preferences
and beliefs regarding route of chemotherapy administration.
Patients rated statements from 1 (strongly agree) to 5
(strongly disagree). The willingness to accept additional
costs for oral chemotherapy was also surveyed. RE-
SULTS: Of 39 patients assessed, 56% stated a preference
for oral chemotherapy, 28% preferred IV chemotherapy,
and 15% had no preference. Interestingly, even patients
stating a preference for IV therapy were willing to pay an
average of $450 per cycle for oral chemotherapy. While
oral preference patients were willing to pay $687 out-of-
pocket per cycle of chemotherapy.
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DISCUSSION: In general, patients preferred home treat-
ment to clinic treatment, and felt strongly that oral che-
motherapy was more convenient and not less effective.
This study suggests that many patients with recurrent
ovarian cancer value their time away from a clinical set-
ting and prefer oral chemotherapy at home. The reason
why patients prefer oral therapy is convenience and effec-
tiveness.
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RESOURCE USE AND COST ASSOCIATED WITH 
MICRO- AND MACROVASCULAR 
COMPLICATIONS IN PATIENTS WITH 
TYPE 2 DIABETES
Goertz A1, Spannheimer A2, Reitberger U2, Liebl A3, Neiss A4
1SmithKline Beecham Pharmaceuticals, Munich, Germany; 
2Kendle International Inc., Munich, Germany; 3Diabetes Center 
Bogenhausen, Munich, Germany; 4Institute for Medical Statistics 
and Epidemiology at the Technical University, Munich, 
Germany
OBJECTIVES: To estimate the effect of major micro-
and macrovascular complications on resource use and
cost in diabetic type 2 patients in Germany. METHODS:
Estimates for complication subgroups were based on re-
sults from the CODE-2 cost of illness study. The German
arm of the study analyzed data on resource utilisation of
809 patients with diabetes type 2 for 1998. A stratified
random sampling technique also allowed analysis for
rare subgroups. Direct and indirect cost were analysed
from a sickness fund perspective. RESULTS: The analysis
indicates that overall cost rises dramatically with devel-
opment of complications. The major cost driver was hos-
pitalization (see table below). CONCLUSIONS: The
study demonstrates the substantial cost burden; this sug-
Patient Reported Preferences and Beliefs, 1  strongly 
agree
Questions Oral (n  22)
IV 
(n  11)
IV more effective 3.1 3.3
Pills more effective 3.4 4.0
IV at clinic convenient 2.6* 1.0*
Pills convenient 0.4 1.2
Prefer pills at home 2.1* 3.6*
Worry about IV line started 3.2* 4.6*
Worry over emesis with pills 3.4 3.8
Questions
No Preference 
(n  6) P-value
IV more effective 3.5
Pills more effective 3.3
IV at clinic convenient 2.2 P  0.003
Pills convenient 1.5 P  0.025
Prefer pills at home 2.5 P  0.002
Worry about IV line started 2.8
Worry over emesis with pills 2.3
gests cost savings by preventing micro- and macrovascu-
lar complications.
PDB2
THE EFFECTS OF AGE AND COMPLICATIONS 
ON THE COST OF MANAGING MEMBERS WITH 
TYPE 1 DIABETES MELLITUS
Martinson MS, Liao E, Newell JA
PharMetrics, Inc., Boston, MA, USA
Complications of Type 1 diabetes mellitus (DM) increase
costs to the healthcare provider. Age is correlated with
complications as well as costs. OBJECTIVE: To estimate
diabetes-related costs due to complications separately
from age. METHODS: Members with Type 1 DM were
selected by ETG group from PharMetric’s Integrated
Outcomes database during 1997. Charges to the mem-
ber’s MCO for ED, pharmacy, in- and out-patient services
were tallied over CY 1997. Members were classified: (1)
as having 0,1, or 1 complications (nephropathy, retin-
opathy, neuropathy, or CAD), and (2) by age: 18, 18–44,
45–64, or 65. A regression of age and gender on
ln(charges) was compared to a regression of age, gender,
and complications. RESULTS: Over 41,000 members
were included in the study, about half male and female.
About 2/3 were 45 or older. Approximately 21,000
(52%) had 0 comorbidities, 12,000 (29%) had 1, and
7800 (19%) had 1; 92% of those 18 had 0 comor-
bidities; 65% of those 18–44 did; 47% of those 45–64
did; 34% of those 65 did. Similarly, 0.3% of those
18 had 1 comorbidity; 10% of those 18–44s, 21% of
No 
complications
Only 
macrovascular 
complications
Time since diagnosis 
of diabetes 6.5 8.4
Percentage of patients 
hospitalized 14% 26%
Number of days in hospital 
per patient and year 2.0 6.5
Hospitalization costs per 
patient and year [DM] 1,007 3,832
Total costs per patient 
and year [DM] 3,370 6,723
Only 
microvascular 
complications
Macro  
microvascular 
complications
Time since diagnosis of 
diabetes 10.6 12.6
Percentage of patients 
hospitalized 24% 41%
Number of days in hospital 
per patient and year 6.7 11.3
Hospitalization costs per 
patient and year [DM] 3,150 6,867
Total costs per patient 
and year [DM] 6,563 11,034
